AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company ...

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in ...

Discovering AnaptysBio: A Closer Look AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in ...

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in ...

North European Oil Royalty Trust (NRT) is expected to report for 1Q. Oncolytics Biotech Inc (ONC.T,ONCY) is expected to report $-0.09 for 4Q. Opus Genetics Inc (IRD) is expected to report $-0.15 for ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.40.

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ANAB: AnaptysBio NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...